Discontinued — last reported Q1 '18
Danaher Allowance for Doubtful Accounts Receivable (Current) decreased by 0.8% to $119.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 11.9%, from $135.00M to $119.00M. Over 4 years (FY 2020 to FY 2024), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -3.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $117.00M | $121.00M | $124.00M | $130.00M | $120.00M | $117.00M | $126.00M | $125.00M | $130.00M | $136.00M | $120.00M | $123.00M | $132.00M | $135.00M | $113.00M | $115.00M | $120.00M | $119.00M |
| QoQ Change | — | +3.4% | +2.5% | +4.8% | -7.7% | -2.5% | +7.7% | -0.8% | +4.0% | +4.6% | -11.8% | +2.5% | +7.3% | +2.3% | -16.3% | +1.8% | +4.3% | -0.8% |
| YoY Change | — | — | — | — | +2.6% | -3.3% | +1.6% | -3.8% | +8.3% | +16.2% | -4.8% | -1.6% | +1.5% | -0.7% | -5.8% | -6.5% | -9.1% | -11.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.